CCL18 and breast carcinoma: In agreement with previous data, the proportions of CD44+CD24- and ALDH1+ breast CSCs were dramatically increased among breast cancer cells cocultured with CCL18-activated NBFs but not with treatment-naive or TGF-β-treated NBFs (Fig. 4E, F).